SCHEMBL5161058

SCHEMBL5161058

O=C1C=C(Nc2ccccc2)C(Nc2ccccc2)=CC1=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.64
L3MBTL1 Q9Y468 5/20 0.64
ALDH1A1 P00352 5/20 0.64
SMN1; SMN2 Q16637 4/20 0.64
MAPK1 P28482 4/20 0.64
MEN1 O00255 4/20 0.64
KMT2A Q03164 4/20 0.64
CASP3 P42574 4/20 0.64
BLM P54132 4/20 0.64
SENP8 Q96LD8 4/20 0.64
SENP7 Q9BQF6 4/20 0.64
SENP6 Q9GZR1 4/20 0.64
LMNA P02545 3/20 0.64
HTT P42858 3/20 0.64
RAB9A P51151 3/20 0.64
APAF1 O14727 3/20 0.64
NPC1 O15118 2/20 0.64
SAE1 Q9UBE0 2/20 0.64
UBA2 Q9UBT2 2/20 0.64
NFKB1 P19838 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL755665 0.90 MAPT (0.64) MAPTL3MBTL1ALDH1A1SMN1; SMN2MAPK1
SCHEMBL29633257 0.79 MAPT (1.00) MAPTL3MBTL1ALDH1A1SMN1; SMN2MAPK1
SCHEMBL17817052 0.79 MAPT (0.53) MAPTL3MBTL1ALDH1A1SMN1; SMN2MAPK1
SCHEMBL30587682 0.79 MAPT (1.00) MAPTL3MBTL1ALDH1A1SMN1; SMN2MAPK1
SCHEMBL754259 0.79 MAPT (1.00) MAPTL3MBTL1ALDH1A1SMN1; SMN2MAPK1
SCHEMBL6409344 0.79 MAPT (1.00) MAPTL3MBTL1ALDH1A1SMN1; SMN2MAPK1
SCHEMBL2037194 0.78 MAPT (0.52) MAPTL3MBTL1ALDH1A1SMN1; SMN2MAPK1
SCHEMBL28408126 0.78 MAPT (0.96) MAPTL3MBTL1ALDH1A1SMN1; SMN2MAPK1
SCHEMBL21819038 0.78 MAPT (0.51) MAPTL3MBTL1ALDH1A1SMN1; SMN2MAPK1
SCHEMBL9333371 0.78 MAPT (0.61) MAPTL3MBTL1ALDH1A1SMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1754514-A1 Agent and method for colouring keratin fibres Wella Aktiengesellschaft (DE) 2007-02-21 EP claimed
US-20070000073-A1 Agent and method for colouring keratin fibres PROCTER & GAMBLE COMPANY, THE 2007-01-04 US claimed
WO-2006094217-A2 AGENT AND METHOD FOR COLOURING KERATIN FIBRES THE PROCTER & GAMBLE COMPANY (US) 2006-09-08 WO claimed
US-7070625-B2 Agent and method for coloring keratin fibers containing 2-benzothiazolinone-hydrazone and quinone derivatives WELLA AG (DE) 2006-07-04 US claimed
EP-1448540-A1 AGENT AND METHOD FOR COLORING KERATIN FIBERS CONTAINING 2-BENZOTHIAZOLINONE-HYDRAZONE AND QUINONE DERIVATIVES Wella Aktiengesellschaft (DE) 2004-08-25 EP claimed
US-20040060124-A1 Agent and method for coloring keratin fibers containing 2-benzothiazolinone-hydrazone and quinone derivatives HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) 2004-04-01 US claimed
WO-2003042199-A1 AGENT AND METHOD FOR COLORING KERATIN FIBERS CONTAINING 2-BENZOTHIAZOLINONE-HYDRAZONE AND QUINONE DERIVATIVES WELLA AKTIENGESELLSCHAFT (DE) 2003-05-22 WO claimed
US-5879411-A Composition and method for dyeing keratin fibers with o-benzoquinones and amino- or hydroxy-containing compounds WELLA AG (DE) 1999-03-09 US claimed
EP-0848942-A1 Composition and method for dyeing keratin fibres Wella Aktiengesellschaft (DE) 1998-06-24 EP claimed
EP-1754514-A1 Agent and method for colouring keratin fibres Wella Aktiengesellschaft (DE) 2007-02-21 EP disclosed
US-20070000073-A1 Agent and method for colouring keratin fibres PROCTER & GAMBLE COMPANY, THE 2007-01-04 US disclosed
WO-2006094217-A2 AGENT AND METHOD FOR COLOURING KERATIN FIBRES THE PROCTER & GAMBLE COMPANY (US) 2006-09-08 WO disclosed
US-7070625-B2 Agent and method for coloring keratin fibers containing 2-benzothiazolinone-hydrazone and quinone derivatives WELLA AG (DE) 2006-07-04 US disclosed
EP-1448540-A1 AGENT AND METHOD FOR COLORING KERATIN FIBERS CONTAINING 2-BENZOTHIAZOLINONE-HYDRAZONE AND QUINONE DERIVATIVES Wella Aktiengesellschaft (DE) 2004-08-25 EP disclosed
US-20040060124-A1 Agent and method for coloring keratin fibers containing 2-benzothiazolinone-hydrazone and quinone derivatives HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) 2004-04-01 US disclosed
WO-2003042199-A1 AGENT AND METHOD FOR COLORING KERATIN FIBERS CONTAINING 2-BENZOTHIAZOLINONE-HYDRAZONE AND QUINONE DERIVATIVES WELLA AKTIENGESELLSCHAFT (DE) 2003-05-22 WO disclosed
US-5879411-A Composition and method for dyeing keratin fibers with o-benzoquinones and amino- or hydroxy-containing compounds WELLA AG (DE) 1999-03-09 US disclosed
EP-0848942-A1 Composition and method for dyeing keratin fibres Wella Aktiengesellschaft (DE) 1998-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040060124-A1 Agent and method for coloring keratin fibers containing 2-benzothiazolinone-hydrazone and quinone derivatives KRT18, NDUFA1, NDUFA2 MAPT 1723/4885L3MBTL1 4803/4885ALDH1A1 33/4885
US-20070000073-A1 Agent and method for colouring keratin fibres KRT18, CDC73, OAT MAPT 1013/4885L3MBTL1 4858/4885ALDH1A1 494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.